ADVANCE showed that Preterax* significantly reduces total mortality by 14% and the risk of cardiovacular death by 18%.
In absolute terms, one death would be avoided for every 79 patients treated with Preterax for five years.

In addition, patients receiving Preterax achieved a significant 14% reduction in total coronary events and a 21% reduction in renal events.

That means that one coronary event would be avoided for every 75 patients treated with Preterax for five years and one renal event would be avoided for every 20 patients treated with Pteterax for five years.

"The results of ADVANCE should have major implications for guidelines, clinical care and public policies", says co-principal study organizer Professor Stephen MacMahon from The George Institute for Global Health, Sydney, Australia, and he adds "These results represent an important step forward in health care for the millions of people with diabetes worldwide. This treatment reduced the likelihood of dying from the complications of diabetes by almost one-fifth, with virtually no side-effetcs".



*Perindopril / indapamide combinations are registered under the following trade names: Preterax, BiPreterax, Preterax Forte, Biprel, Noliprel, Noliprel Forte, Prelectal, Prelectal forte, Predonium, Noliprel, Coversyl Plus, Coversyl Comp, Coversum Combi, Armix Comb, Prestarium Combi, Prestarium Plus.